Explanipedia

Author Correction: Classification of GBA1 variants and their impact on Parkinson’s disease: an in silico score analysis Open

Christelle Tesson, Aymeric Basset, François-Xavier Lejeune, Guillaume Cogan, Graziella Mangone , et al. · 2025

Parkinson’s disease and multiple system atrophy are gateways to <i>RFC1</i>-related disorders Open

Violette Delforge, Giulia Coarelli, Eugénie Mutez, Anne‐Sophie Rolland, Anna Wissocq , et al. · 2025

Biallelic pathogenic expansions of the RFC1 gene are the genetic cause of cerebellar ataxia, neuropathy, and bilateral vestibular areflexia syndrome. Sensory neuropathy is the most common symptom, but the clinical impairments and gateways …

Classification of GBA1 variants and their impact on Parkinson’s disease: an in silico score analysis Open

Aymeric Lanore, Christelle Tesson, Aymeric Basset, François-Xavier Lejeune, Guillaume Cogan , et al. · 2025

Non-motor subtypes in candidates for subthalamic deep brain stimulation for Parkinson's disease Open

Hélène Ducrocq, Salomé Puisieux, Lucie Hopes, Solène Frismand, Sophie Colnat‐Coulbois , et al. · 2025

The mainly-motor (Cluster 1), mainly non-motor (Cluster 3), and intermediate (Cluster 2) NMS endophenotypes must be replicated in an independent cohort but may help stratify patients for management (pharmacological, deep-brain stimulation,…

Exploring the link between personality dimensions and non-motor fluctuations in Parkinson's disease Open

Mathilde Boussac, Florent Faggianelli, Estelle Harroch, Alexandre Eusébio, Margherita Fabbri , et al. · 2025

Background Parkinson's disease (PD) patients on dopaminergic drugs may experience non-motor fluctuations (NMFs) which are often heterogeneous and respond variably to treatments. Objective We evaluated if personality was associated to NMFs …

Parkinson's Disease, Speech and Neurosurgery Open

Thomas Ollivier, Serge Pinto, Anne‐Sophie Rolland, Émeline Cailliau, Gustavo Touzet , et al. · 2025

Background Speech impairment is a recognized but unpredictable adverse effect of sub‐thalamic nucleus deep brain stimulation (STN‐DBS) for Parkinson's disease (PD). Objectives To evaluate the prevalence of speech impairment 1 year after ST…

Intracerebroventricular anaerobic dopamine in Parkinson’s disease with l-dopa-related complications: a phase 1/2 randomized-controlled trial Open

Caroline Moreau, Pascal Odou, Julien Labreuche, Alexandre Demailly, Gustavo Touzet , et al. · 2025

Expression of concern: Sensing of COVID-19 spike protein in nasopharyngeal samples using a portable surface plasmon resonance diagnostic system Open

Hiba Saada, Quentin Pagneux, James Cheng‐Chung Wei, Ludovic S. Live, Alain Roussel , et al. · 2024

Expression of concern for ‘Sensing of COVID-19 spike protein in nasopharyngeal samples using a portable surface plasmon resonance diagnostic system’ by Hiba Saada et al. , Sens. Diagn. , 2022, 1 , 1021–1031, https://doi.org/10.1039/D2SD000…

Dysregulation of muscle cholesterol transport in amyotrophic lateral sclerosis Open

Delphine Sapaly, Flore Cheguillaume, Laure Weill, Zoé Clerc, Olivier Biondi , et al. · 2024

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting motor neurons, with a typical lifespan of 3–5 years. Altered metabolism is a key feature of ALS that strongly influences prognosis, with an increase …

Caffeine consumption outcomes on amyotrophic lateral sclerosis disease progression and cognition Open

Vincent Huin, David Blum, Violette Delforge, Émeline Cailliau, Sofia Djeziri , et al. · 2024

Caffeine consumption outcomes on Amyotrophic Lateral Sclerosis (ALS) including progression, survival and cognition remain poorly defined and may depend on its metabolization influenced by genetic variants. 378 ALS patients with a precise e…

Pharmacological neuromodulation by intracerebroventricular administration of anaerobic dopamine in the treatment of advanced Parkinson's disease Open

David Devos, Caroline Moreau, Pascal Odou, Julien Labreuche, Alexandre Demailly , et al. · 2024

Continuous compensation of cerebral dopamine deficiency represents an ideal treatment for Parkinson's disease. However, dopamine does not cross the digestive and blood-brain barriers, and is rapidly oxidised. The new concept is continuous …

The Use of Image Guided Programming to Improve Deep Brain Stimulation Workflows with Directional Leads in Parkinson’s Disease Open

Anne‐Sophie Rolland, Gustavo Touzet, Nicolas Carrière, Eugénie Mutez, Alexandre Kreisler , et al. · 2023

Background: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a preferred treatment for parkinsonian patients with severe motor fluctuations. Proper targeting of the STN sensorimotor segment appears to be a crucial factor fo…

Trial of Deferiprone in Parkinson’s Disease Open

David Devos, Julien Labreuche, Olivier Rascol, Jean‐Christophe Corvol, Alain Duhamel , et al. · 2022

In participants with early Parkinson's disease who had never received levodopa and in whom treatment with dopaminergic medications was not planned, deferiprone was associated with worse scores in measures of parkinsonism than those with pl…

Can Dopamine Responsiveness Be Predicted in Parkinson’s Disease Without an Acute Administration Test? Open

Nacim Betrouni, Caroline Moreau, Anne‐Sophie Rolland, Nicolas Carrière, Romain Viard , et al. · 2022

Background: Dopamine responsiveness (dopa-sensitivity) is an important parameter in the management of patients with Parkinson’s disease (PD). For quantification of this parameter, patients undergo a challenge test with acute Levodopa admin…

Limbic Stimulation Drives Mania in <span>STN‐DBS</span> in Parkinson Disease: A Prospective Study Open

Stéphane Prange, Zhengyu Lin, Mikaïl Nourredine, Téodor Danaila, Chloé Laurencin , et al. · 2022

In this one‐year prospective study, Parkinson's disease (PD) patients with or without mania following STN‐DBS were compared to investigate risk and etiological factors, clinical management and consequences. Eighteen (16.2%) out of 111 cons…

SARS-CoV-2 detection using a nanobody-functionalized voltammetric device Open

Quentin Pagneux, Alain Roussel, Hiba Saada, Christian Cambillau, Béatrice Amigues , et al. · 2022

Heterogeneity of PD-MCI in Candidates to Subthalamic Deep Brain Stimulation: Associated Cortical and Subcortical Modifications Open

Quentin Devignes, Sami Daoudi, Romain Viard, Renaud Lopes, Nacim Betrouni , et al. · 2022

Background: Parkinson’s disease mild cognitive impairment (PD-MCI) is frequent and heterogenous. There is no consensus about its influence on subthalamic deep brain stimulation (STN-DBS) outcomes. Objective: To determine the prevalence of …

Sensing of COVID-19 spike protein in nasopharyngeal samples using a portable surface plasmon resonance diagnostic system Open

Hiba Saada, Quentin Pagneux, James Cheng‐Chung Wei, Ludovic S. Live, Alain Roussel , et al. · 2022

Rapid, yet sensitive and accurate testing concepts are critical in the control of spreading viral diseases.

Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinson’s Disease (PSYCHO-STIM II) Open

Mathilde Boussac, Christophe Arbus, Hélène Klinger, Alexandre Eusébio, Élodie Hainque , et al. · 2021

Background: Deep brain stimulation of the sub-thalamic nucleus (DBS-STN) reduces symptoms in Parkinson’s disease (PD) patients with motor fluctuations. However, some patients may not feel ameliorated afterwards, despite an objective motor …

Preoperative REM Sleep Behavior Disorder and Subthalamic Nucleus Deep Brain Stimulation Outcome in Parkinson Disease 1 Year After Surgery Open

Elsa Besse-Pinot, Bruno Pereira, Franck Durif, Maria Livia Fantini, E. Durand , et al. · 2021

This study provides Class II evidence that in patients with PD eligible for STN-DBS, the presence of probable RBD preoperatively is not associated with poorer outcomes 1 year post surgery.

Assessing the upper motor neuron in amyotrophic lateral sclerosis using the triple stimulation technique: A multicenter prospective study Open

Aude‐Marie Grapperon, Annie Verschueren, Élisabeth Jouve, Régine Morizot-Koutlidis, Timothée Lenglet , et al. · 2021

Texture-based markers from structural imaging correlate with motor handicap in Parkinson’s disease Open

Nacim Betrouni, Caroline Moreau, Anne‐Sophie Rolland, Nicolas Carrière, Marie Chupin , et al. · 2021

Personality dimensions of patients can change during the course of parkinson’s disease Open

Mathilde Boussac, Christophe Arbus, Julia Dupouy, Estelle Harroch, Vanessa Rousseau , et al. · 2021

Background Studies assessing personality dimensions by the “Temperament and Character Inventory” (TCI) have previously found an association between Parkinson’s disease (PD) and lower Novelty Seeking and higher Harm Avoidance scores. Here, …

Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations Open

Graziella Mangone, Samir Bekadar, Florence Cormier‐Dequaire, Khadija Tahiri, Arlette Welaratne , et al. · 2020

Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease Open

Caroline Moreau, Anne‐Sophie Rolland, Elsa Y. Pioli, Qin Li, Pascal Odou , et al. · 2020

Continuous circadian i.c.v. of A-dopamine appears to be feasible and shows efficacy without dyskinesia with a safe therapeutic index.

Author Correction: A ferroptosis–based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis Open

David Devos, Caroline Moreau, Maéva Kyheng, Guillaume Garçon, Anne‐Sophie Rolland , et al. · 2020

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Conservative iron chelation for neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis Open

David Devos, Z. Ioav Cabantchik, Caroline Moreau, Véronique Danel, Laura Mahoney‐Sanchez , et al. · 2020

Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates Open

Flore Gouel, Anne‐Sophie Rolland, Jean‐Christophe Devedjian, Thierry Burnouf, David Devos · 2019

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that typically results in death within 3-5 years after diagnosis. To date, there is no curative treatment and therefore an urgent unmet need of neuroprotective and/or…

A ferroptosis–based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis Open

David Devos, Caroline Moreau, Maéva Kyheng, Guillaume Garçon, Anne‐Sophie Rolland , et al. · 2019

Nouvelle stratégie de neuroprotection basée sur la chélation conservatrice du fer dans la maladie de Parkinson Open

Anne‐Sophie Rolland, Caroline Moreau, Jean-Christophe Devedjian, Dominique Deplanque, Régis Bordet , et al. · 2019

Anne‐Sophie Rolland YOU? Author Swipe